Image Place holder

Omar A. Castaneda Puglianini, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Dr. Castaneda Puglianini’s clinical and research interests include autologous and allogeneic hematopoietic stem cell transplantation and immunotherapy for plasma cell malignancies.

Education & Training

Board Certification:

  • Internal Medicine
  • Internal Medicine

Fellowship:

  • Virginia Commonwealth University Massey Cancer Center - Hematology and Oncology
  • H. Lee Moffitt Cancer Center and Research Institute - Blood and Marrow Transplantation

Residency:

  • Albert Einstein College of Medicine Jacobi Medical Center - Internal Medicine

Medical School:

  • Universidad Peruana Cayetano Heredia Alberto Hurtado School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Condition: Malignant Hematology
Intervention: Rituxan (rituximab); Rituxan Hycela; rituximab
Open

CLINICAL TRIAL 19800
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Condition: Malignant Hematology
Intervention: KD025
Open

CLINICAL TRIAL 19722
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Condition: Malignant Hematology
Intervention: bb2121; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19961
A Phase 1B/2 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Eq001 In Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Condition: Malignant Hematology
Intervention: EQ001; Placebo
Open

CLINICAL TRIAL 19813
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (Karmma-3)
Condition: Malignant Hematology
Intervention: Bortezomib; CC-4047 (Pomalidomide); CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Ixazomib (Ninlaro); Lenalidomide (Revlimid); PS-341 (Bortezomib); Pomalidomide; Velcade (Bortezomib); bb2121; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 20036
Phase II trial of APR-246 in combination with azacitidine as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplant
Condition: Malignant Hematology
Intervention: APR-246; azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 19158
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Casas J, Castañeda O, Prezza P, Castillo M, Llosa L. [An unusual presentation of liver involvement in hereditary hemorrhagic telangiectasia biliary disease]. Rev Gastroenterol Peru. 2009 Jul;29(3):266-271. Pubmedid: 19898600.